Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations (Orca)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03929861
Recruitment Status : Completed
First Posted : April 29, 2019
Last Update Posted : April 29, 2019
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:
Primary Objective: To compare the bioavailability of a single dose of fluconazole 150 mg capsules (Test product) with the bioavailability of a single dose of Diflucan™ capsules, 150 mg (Reference) administered under fasting conditions in order to assess bioequivalence Secondary Objectives: To assess safety and tolerability in form of adverse events and clinical parameters (systolic/diastolic blood pressure, pulse rate, body temperature, physical examination, electrocardiogram, clinical laboratory testing, and overall tolerability) and to assess further pharmacokinetic parameters of fluconazole

Condition or disease Intervention/treatment Phase
Pharmacology, Clinical Drug: Fluconazole (BAYT006267) 150 mg capsules Drug: Fluconazole 150 mg capsules (DiflucanTM) Phase 1

Detailed Description:
Clinical pharmacology

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-label, Randomized, Two-treatment, Two-period, Two-sequence, Cross-over, Mono-center Bioequivalence Study to Compare Single Doses of Fluconazole 150 mg Capsule (Test Product) With Diflucan™ Capsule 150 mg (Reference) in Healthy Volunteers
Actual Study Start Date : July 31, 2012
Actual Primary Completion Date : September 10, 2012
Actual Study Completion Date : September 10, 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Fluconazole

Arm Intervention/treatment
Experimental: Fluconazole, period 1
Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
Drug: Fluconazole (BAYT006267) 150 mg capsules
Fluconazole 150 mg

Drug: Fluconazole 150 mg capsules (DiflucanTM)
Fluconazole 150 mg

Experimental: Fluconazole, period 2
Subjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours
Drug: Fluconazole (BAYT006267) 150 mg capsules
Fluconazole 150 mg

Drug: Fluconazole 150 mg capsules (DiflucanTM)
Fluconazole 150 mg




Primary Outcome Measures :
  1. Cmax [ Time Frame: Pre-dose and up to 72 hours post-dose ]
    Concentration maximum

  2. AUC0-tlast [ Time Frame: Pre-dose and up to 72 hours post-dose ]
    Area under the plasma concentration time curve from time 0 to the last data point above the lower limit of quantification


Secondary Outcome Measures :
  1. Number of participants with Adverse Events as a Measure of safety and tolerability [ Time Frame: Up to 7 weeks ]
  2. tmax [ Time Frame: Pre-dose and up to 72 hours post-dose ]
    Time of maximum concentration

  3. t½λz [ Time Frame: Pre-dose and up to 72 hours post-dose ]
    Half-life associated with the terminal slope

  4. MRT [ Time Frame: Pre-dose and up to 72 hours post-dose ]
    Mean residence time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males in the age between 18 and 50 years
  • Subjects with a body weight of at least 50 kg and a BMI between 18.5 and 30.0 kg/m2
  • Subjects had to be willing to use an acceptable method of contraception (double barrier) during the study and 2 weeks after the end of the study
  • All subjects had to give their written informed consent prior to admission to the trial
  • Legal capacity and subject ability to understand the nature, scope and risk/benefit of the trial

Exclusion Criteria:

  • Any finding of physical examination (including blood pressure, pulse rate, and ECG) deviating from normal and of clinical relevance
  • Positive test for hepatitis B surface antigen test, anti hepatitis C virus (anti-HCV), or human immunodeficiency virus (HIV)-1/2 antibodies and HIV-1 p24-antigen
  • Positive drug screen test (verified by "Mahsan-Kombi/DOA2" and "Kombi 4/O2TSchnelltest"), or any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine, opiates, and cannabis abuse
  • More than moderate alcohol consumption (>40 g of alcohol regularly per day)
  • Demonstrated excess in xanthine consumption (more than 5 cups of coffee or equivalent per day)
  • Subjects with known hypersensitivity to fluconazole and any other excipient of the test products and subjects with lactose intolerance
  • Subjects with known hypersensitivity to other azoles
  • Any need of medication during the trial except allowed medication (paracetamol up to 1 g a day)
  • Any concomitant medication, including herbal remedies, within 10 days before administration of the investigational medicinal product (IMP), or within a period shorter than 10 times the elimination half-life of the respective medication
  • History of severe allergies, non-allergic drug reactions, multiple drug allergies or active hay fever
  • Any active disease, acute or chronic
  • Febrile or infectious illness within 1 week before screening
  • Any other disease or condition which could influence the metabolism of the drug (e.g., endocrine diseases)
  • Any gastrointestinal complaints within 1 week before screening (gastrointestinal disorders including irritable bowel and gastrointestinal ulcer)
  • Any relevant history of chronic or recurrent metabolic, renal, hepatic, pulmonary, gastrointestinal (especially history of chronic gastritis or peptic ulcers), neurological (especially history of epileptic seizures), endocrinological, immunological, psychiatric or cardiovascular disease, myopathies and bleeding disorders
  • Subjects with QTc intervals of more than 450 ms calculated by Bazett's formula
  • Subjects with a pulse rate below 50 or above 90 beats per minute
  • Subjects with serum creatinine concentrations outside the range of <1.20 mg/dL
  • Subjects with a medical disorder, condition or history of such that could impair the subject's ability to participate or complete this trial in the opinion of the Investigator
  • Participated in the treatment phase of another clinical trial within 30 days prior to first administration of the IMP
  • Blood donation or blood sample collection exceeding 200 mL within the last 30 days
  • Unwilling or unable to comply with all requirements outlined in the protocol
  • Excessive sports or sauna within 5 days before start of the treatment phase
  • Consumption of xanthine- and quinine-containing food and beverages and certain fruit juices such as grapefruit juice within 72 h before IMP administration
  • Alcohol consumption within 24 h before screening and within 72 h before IMP administration (on Day -1 verified by alcohol breath test)
  • History of alcohol or drug abuse within the last 5 years
  • History of smoking (within the last 12 months before screening)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03929861


Locations
Layout table for location information
Germany
Mannheim, Baden-Württemberg, Germany, 68167
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03929861     History of Changes
Other Study ID Numbers: 16165
2011-006159-13 ( EudraCT Number )
First Posted: April 29, 2019    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: April 2019

Keywords provided by Bayer:
Fluconazole
bioequivalence
capsule

Additional relevant MeSH terms:
Layout table for MeSH terms
Fluconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors